Patent details

92175 Product Name: "lixisénatide"

Basic Information

Publication number:
92175
Type:
SPC
SPC Type:
Medical
Basic Patent Number:
EP009456567
Legal Status:
Active
Application number:
92175
First applicant's nationality:
Procedural language:
French

Marketing Authorization

Marketing Authorization Number:
EU/1/12/811/001-005 - Lyxumia - lixisénatide
Marketing Authorization Type:
Marketing Authorization Date:
01/02/2013
Marketing Authorization Status:
Accepted
Marketing Authorization Country:

Dates

Filing date:
27/03/2013
First Marketing Authorization date:
01/02/2013
Grant date:
27/05/2013
Activation date:
12/07/2020
Publication date:
27/05/2013
Lapsed date:
Expiration date:
Renunciation date:
Revocation date:
Annulment date:
Basic SPC Expiration:
12/07/2025
SPC Extension Expiration:
12/07/2025
Rejection date:
Withdrawal date:

Owner

From:
09/09/2015
 
 

Name:
ZP HOLDING SPV K/S
Address:
SMEDELAND 36, 2600 GLOSTRUP, Denmark (DK)

History of Owners

From:
27/03/2013
To:
08/09/2015

Name:
Zealand Pharma A/S
Address:
Smedeland 26B, 2600 Glostrup, Denmark (DK)

Agent

Name:
OFFICE FREYLINGER S.A.
From:
27/03/2013
Address:
Boîte Postale 48, L-8001, STRASSEN, Luxembourg (LU)
To:

Inventor

1

Name:
LARSEN Bjarne, Due
Address:
Denmark (DK)

2

Name:
MIKKELSEN Jens, Damsgaard
Address:
Denmark (DK)

3

Name:
NEVE Soren
Address:
Denmark (DK)

Publication

Bulletin

Bulletin Heading:
SPC3
Bulletin edition number:
2020/09
Publication date:
04/08/2020
Description:
Section E : Supplementary Protection certificates entered into force – IA publication

Annual Fees

Annual Fee Due Date:
Annual Fee Number:
Expected Payer:
Last Annual Fee Payment Date:
07/06/2024
Last Annual Fee Paid Number:
25
Last Annual Fee Paid Amount:
450 Euro
Payer:
OFFICE FREYLINGER S.A.
Filing date Document type Number of pages